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ABSTRACT
Pituitary spindle cell oncocytoma (SCO) is an uncommon primary pituitary 
neoplasm that presents with mass effect on adjacent neurovascular structures, 
similar to non-hormone-producing pituitary adenomas. To determine the molecular 
etiology of SCO, we performed exome sequencing on four SCO cases, with matched 
normal controls, to assess somatic mutations and copy number alterations. Our 
analysis revealed a low mutation rate and a copy-neutral profile, consistent with 
the low-grade nature of this tumor. However, we identified a co-occurring somatic 
HRAS (p.Q61R) activating point mutation and MEN1 frameshift mutation (p.L117fs) 
present in a primary and recurrent tumor from one patient. Other SCOs demonstrated 
mutations in SND1 and FAT1, which are associated with MAPK pathway activation. 
Immunohistochemistry across the SCO cohort demonstrated robust MAPK activity in 
all cases (n=4), as evidenced by strong phospho-ERK staining, while phospho-AKT 
levels suggested only basal levels of PI3K pathway activation. Taken together, this 
identifies the MAPK signaling pathway as a novel therapeutic target for spindle cell 
oncocytoma, which may offer a powerful adjunct for aggressive tumors refractory to 
surgical resection.
INTRODUCTION
Spindle cell oncocytoma (SCO) is a rare non-
endocrine neoplasm of the hypophysis, which exhibits 
WHO grade I histology [1]. SCO presents similarly to non-
functioning pituitary adenomas, clinically demonstrating 
pituitary hypofunction, visual field deficits, and potential 
headache and nausea, due to mass effect. Although they 
were initially regarded as benign, several subsequent 
recurrent and locally aggressive SCO cases have been 
reported [2–6]. SCO is primarily treated with surgical 
resection, while radiation therapy has been reported for 
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patients with recurrence [2]. Invasion of nearby structures, 
including the cavernous sinus, suprasellar space, and 
sphenoid sinus, can challenge traditional therapeutic 
strategies.
Histologically, SCOs show an interlacing fascicular 
pattern of spindled to epithelioid cells, with eosinophilic and 
variably oncocytic cytoplasm. Nuclear atypia is generally 
minimal and mitotic indices are low [2]. Ultrastructural 
features of abundant mitochondria and a paucity of secretory 
granules help distinguish SCOs from non-functioning 
adenomas [1, 2]. Expression of S-100, vimentin, galectin-3, 
and epithelial membrane antigen (EMA) is typical of SCOs, 
which lack expression of pituitary adenoma markers such as 
synaptophysin, chromogranin, and pituitary hormones [1]. 
SCOs generally do not express glial fibrillary acidic protein 
(GFAP), distinguishing them from pituicytoma, a tumor 
derived from neurohypophyseal glial pituicytes [1, 2, 7]. 
SCOs also do not express cytokeratins, smooth muscle actin 
(SMA), CD34, or CD68.
The cell of origin for SCOs remains unclear. They 
have been postulated to derive from folliculostellate cells 
of the adenohypophysis, based on shared expression 
of S-100, vimentin, galectin-3, and EMA, as well as 
desmosomes and intermediate junctions found using 
electron microscopy [1]. However, the pituicyte has also 
been proposed as a potential cell of origin, on the basis 
of shared expression of thyroid transcription factor 1 
(TTF-1), prompting a potential classification of SCOs as 
oncocytic pituicytomas [8].
Little is known about the genetic drivers of 
proliferation and infiltration in SCO. A recent report 
on seven cases found no BRAF V600E mutations, 
BRAF-KIAA fusions, or IDH R132H mutation-specific 
immunoreactivity [8]. One case report observed mild-
to-moderate expression of phospho-AKT, phospho-
mTOR, and GLI2, suggesting some degree of activation 
of mammalian target of rapamycin (mTOR) and sonic 
hedgehog (SHH) pathways [9].
In order to further examine the molecular drivers 
of oncogenesis in spindle cell oncocytoma, we performed 
whole exome sequencing and signal pathway profiling on 
four cases of SCO. Here we report novel genetic mutations 
that may provide additional insights into the future 
treatment of this disease.
RESULTS
Mutational profile of SCO
We identified all cases of SCO resected at 
Brigham and Women’s Hospital since its first report 
at this institution in 2002, yielding four cases from 
three patients (Table 1). Patient three manifested with 
recurrent/residual tumor less than a year after initial 
resection, and therefore two separate samples were 
available for study (cases 3A and 3B). Each SCO case 
was reviewed and the diagnosis confirmed on the basis 
of histologic appearance and immunohistochemical 
profile (Table 2). Figure 1 illustrates typical histologic 
and immunohistochemical features. In concordance 
with a recent report [8], we found strong nuclear TTF-1 
expression in each case of SCO.
We performed whole exome next-generation 
sequencing on each SCO case, using matched DNA as 
control. Sequencing revealed 43 nonsynonymous somatic 
mutations, insertions, or deletions (Table 3). Among the 
mutations present, samples 3A and 3B both showed a 
Q61R mutation in the Harvey rat sarcoma viral oncogene 
homolog (HRAS) gene on chromosome 11, a specific 
variant that has been previously reported in multiple 
cancers [10–13]. Cases 3A and 3B also both showed two 
frameshift mutations in the multiple endocrine neoplasia 
type 1 (MEN1) gene, also on chromosome 11; these 
variants have been previously reported as both germline 
and sporadic mutations in tumors of the pituitary and other 
sites [14].
Other tumor-associated genes found to be mutated 
as single events in individual tumors in the SCOs within 
our cohort include FAT atypical cadherin 1 (FAT1) [15], 
staphylococcal nuclease domain-containing protein 
1 (SND1) [16, 17], Cbl proto-oncogene E3 ubiquitin 
protein ligase (CBL), frizzled class receptor 7 (FZD7), 
phosphatidylinositol-4,5-bisphosphate 3-kinase subunit 
gamma (PIK3CG), and SH3 domain binding kinase 1 
(SBK1).
Copy number profile of SCO
We found no significant recurrent copy number 
changes or aneuploidy across the examined cohort of 
SCO cases. We observed a loss of chromosome 13 in 
case 3A, which was not detected in the recurrent tumor, 
case 3B (Supplementary Figure S1). However, this may 
be attributable to a lower tumor cell fraction in case 3B, 
limiting its detection.
Immunohistochemical assessment of MAPK and 
PI3K signaling pathways
Prompted by the HRAS mutation identified in cases 
3A and 3B, we examined activation of its canonical 
intracellular signaling cascade, the mitogen-activated 
protein kinase (MAPK) pathway. Ras signals activate Raf, 
resulting in phosphorylation of downstream MEK and of 
ERK. This leads to multiple cellular responses, including 
phosphorylation of ribosomal protein S6, which regulates 
protein translation and activates cell cycle regulators. We 
found robust expression (>90% positivity) of downstream 
pathway effectors, phosphorylated ERK (p-ERK) and S6 
(p-S6), in all four SCO cases, using immunohistochemistry 
(Figure 2). In contrast, IHC for phosphorylated protein 
kinase B (p-AKT) showed only a weak signal, indicating 
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basal activation of the phosphoinositide 3-kinase (PI3K) 
pathway.
DISCUSSION
Strong evidence of activated downstream effectors 
of the MAPK pathway in each pituitary SCO tumor in 
this study suggests a perturbation that may drive cellular 
proliferation. In cases 3A and 3B, we identified an HRAS 
Q61R mutation by whole exome sequencing, which is 
associated with multiple other cancers and may have 
caused MAPK pathway activation. Case 2 contained 
a mutation in SND1, which has been reported to be 
involved in glioblastoma and carcinomas of the colon, 
prostate, and liver [16, 18–20]. SND1 is a component 
of the RNA-induced silencing complex (RISC) and has 
been reported to activate the MAP kinase ERK [17]. Case 
1 contained a mutation in the tumor suppressor FAT1 
atypical cadherin gene, which has been implicated in 
glioblastoma, colorectal adenocarcinoma, and head and 
neck squamous cell carcinoma [15]. While FAT1 is best 
known for promoting Wnt signaling, FAT1 expression has 
Table 1: Clinical profiles of spindle cell oncocytoma cases
Case Age (Yr) Imaging characteristics
1 66 2.4 cm sellar mass, abutting cavernous sinuses and third ventricle, and extending into 
sphenoid sinus and posterior to optic chiasm
2 50 1.4 cm sellar mass, partially surrounding bilateral internal carotid arteries and 
abutting optic nerves
3A 63 2.7 cm sellar mass, extending into sphenoid sinus, partially encasing bilateral internal 
carotid arteries, and displacing optic chiasm and optic nerves
3B 63 1.7 cm residual/recurrent enhancing sellar mass, partially encasing left internal 
carotid artery, with displacement of optic chiasm and optic nerves
Table 2: Immunohistochemical profiles of spindle cell oncocytoma cases
Case EMA S100 Galectin-3 GFAP Chromogranin TTF-1 MIB-1
1 + + + - - + 5%
2 + + + - - + 2%
3A - + + - - + 5%
3B + (focal) + + - - + 5%
Figure 1: Histologic and Immunohistochemical Features of Spindle Cell Oncocytoma. A. H&E stain. Immunohistochemistry 
for: B. S100, C. Galectin-3, D. TTF-1, E. EMA, F. Vimentin, G. Chromogranin, H. GFAP, I. CD68 and J. MIB-1 (Ki-67). (A-J, 600X 
magnification; A-I, case 1; J, case 2)
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Table 3: Mutations identified by whole exome sequencing of spindle cell oncocytoma cases
Gene Chr. Variant Protein 
Change
Allele 
Frequency
Case Functional 
Prediction 
Score (SIFT)
NAV1 1 Missense 
Mutation
L85V 0.31, 0.15 3A, 3B 0.00
TCEB3 1 Frameshift 
Deletion
K451fs 0.16 3A —
ADD2 2 Missense 
Mutation
E480K 0.11 1 0.00
C2orf16 2 Nonsense 
Mutation
Q788* 0.39, 0.20 3A, 3B —
FZD7 2 Missense 
Mutation
D3N 0.41, 0.27 3A, 3B 0.30
SH3BP4 2 Missense 
Mutation
D922G 0.14 1 0.00
STAT4 2 Missense 
Mutation
E388D 0.44, 0.25 3A, 3B 0.04
ZNF717 3 Frameshift 
Insertion
T45fs 0.4 2 —
FAT1 4 Missense 
Mutation
N109H 0.25 1 0.00
FAT4 4 Missense 
Mutation
N3706S 0.25 3B 0.10
ANKH 5 Missense 
Mutation
E43D 0.39, 0.09 3A, 3B 0.08
ASCC3 6 Missense 
Mutation
S221Y 0.12 3A 1.00
EXOC2 6 Missense 
Mutation
H736Q 0.33, 0.21 3A, 3B 0.34
GPR115 6 Missense 
Mutation
N230S 0.13 2 0.74
GTPBP2 6 Missense 
Mutation
R335Q 0.11 1 —
PIK3CG 7 Missense 
Mutation
E1073K 0.38, 0.15 3A, 3B 0.47
SND1 7 Missense 
Mutation
S578N 0.18 2 0.17
TRPV5 7 Missense 
Mutation
M440T 0.13 3A 0.25
AGO2 8 Missense 
Mutation
P430R 0.13 2 0.00
C8orf76 8 Frameshift 
Deletion
PERR21fs 0.47 3A —
TRPM6 9 Missense 
Mutation
L333V 0.12, 0.14 3A, 3B 0.14
(Continued )
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Gene Chr. Variant Protein 
Change
Allele 
Frequency
Case Functional 
Prediction 
Score (SIFT)
CALHM1 10 Missense 
Mutation
R178C 0.40, 0.13 3A, 3B 0.02
CBL 11 Missense 
Mutation
R280Q 0.41, 0.21 3A, 3B 0.01
HRAS 11 Missense 
Mutation
Q61R 0.42, 0.19 3A, 3B 0.04
IPO7 11 Nonsense 
Mutation
Y689* 0.21 3B —
MEN1 11 Frameshift 
Deletion
K459fs 0.36, 0.17 3A, 3B —
MEN1 11 Frameshift 
Deletion
LV117fs 0.36, 0.18 3A, 3B —
OR1S2 11 Missense 
Mutation
P300S 0.42, 0.20 3A, 3B 0.00
XRRA1 11 Missense 
Mutation
R76Q 0.12 1 0.77
CCER1 12 Nonsense 
Mutation
R40* 0.13 2 —
ITGA7 12 Missense 
Mutation
D312A 0.42, 0.13 3A, 3B 0.43
TAOK3 12 Missense 
Mutation
E496D 0.39, 0.14 3A, 3B 0.11
CCNK 14 Missense 
Mutation
G53A 0.26 3B 0.27
KLHDC1 14 Frameshift 
Deletion
W28fs 0.36 1 —
LTB4R 14 Nonsense 
Mutation
Y172* 0.35, 0.14 3A, 3B —
RIN3 14 Nonsense 
Mutation
W275* 0.06, 0.21 3A, 3B —
CHD2 15 Missense 
Mutation
R550S 0.19 1 0.00
DENND4A 15 Missense 
Mutation
R865C 0.1 1 0.00
LTK 15 Missense 
Mutation
A480T 0.13 1 0.11
TYRO3 15 Missense 
Mutation
A48V 0.18 2 0.08
SBK1 16 Frameshift 
Deletion
G304fs 0.33 3B —
CD300A 17 Missense 
Mutation
W49L 0.21 3B 0.00
FMNL1 17 Missense 
Mutation
P49R 0.27, 0.10 3A, 3B 0.00
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also been associated with ERK activation [21]. Therefore, 
mutations in HRAS, SND1, and FAT1 may constitute 
separate genetic drivers that underlie the common MAPK 
activation observed in each SCO.
While our immunohistochemical and exome 
sequencing findings point to MAPK pathway activation 
in SCOs, the finding of two MEN1 mutations in cases 3A 
and 3B suggests that biallelic inactivation of MEN1 may 
be a second mechanism underlying neoplasia in SCO. 
Inactivation of both MEN1 alleles has been found in 
multiple endocrine tumors, including parathyroid adenoma, 
insulinoma, and a small subset of pituitary adenomas [22].
HRAS mutations have been previously associated 
with increased aggressiveness in pituitary adenomas 
[23, 24]. Given this, it is noteworthy that cases 3A and 
3B, which displayed rapid recurrence leading to repeat 
resections, demonstrated a pathogenic HRAS mutation. 
As such, HRAS mutation may be an indicator of more 
aggressive behavior in SCO.
The recurrent tumor of case 3B may also be 
related to the acquisition of new somatic mutations not 
present in the initial tumor, case 3A. Newly mutated 
genes identified in case 3B include FAT atypical 
cadherin 4 (FAT4), Importin 7 (IPO7), Cyclin K 
(CCNK), SH3 domain-binding kinase 1 (SBK1), and 
CD300A. Of these, FAT4, CCNK, and SBK1 have 
been previously linked to neoplasia [25–27] and may 
contribute to the aggressive behavior demonstrated by 
case 3.
Interestingly, the similarities in presentation 
between SCOs and pituitary adenomas are reflected in 
their genetic profiles as well. Various MEN1 mutations 
have been implicated in pituitary adenoma [14], and, 
as mentioned earlier, pituitary adenomas with HRAS 
mutations show increased aggressiveness. The genetic 
similarity between SCO case 3 reported here and pituitary 
adenoma raises the question of diagnostic overlap. 
However, the immunohistochemical profile, including the 
absence of neuroendocrine markers and the presence of 
S100, strongly suggest that case 3 is indeed a spindle cell 
oncocytoma, rather than a pituitary adenoma [1, 28–30].
Pituitary adenomas have been associated with 
mutations in numerous other genes, including succinate 
dehydrogenase (SDH) [31], ubiquitin-specific peptidase 
8 (USP8) [32, 33], cyclin-dependent kinase inhibitor 1B 
(CDKN1B) [34], aryl hydrocarbon receptor interacting 
protein (AIP) [35], and cAMP-dependent protein kinase 
type 1-alpha regulatory subunit (PRKAR1A) [36]. These 
mutations were not identified in our whole exome 
sequences of spindle cell oncocytoma. Cytogenetic studies 
of pituitary adenoma have shown scattered chromosome 
gains and losses, without a significant recurrent signature 
Figure 2: MAPK and PI3K Pathway Signaling in Spindle Cell Oncocytoma Cases. Tissue sections were stained with H&E or 
immunohistochemistry for MIB-1, phosphorylated ERK (p-ERK), phosphorylated AKT (p-AKT), and phosphorylated S6 (p-S6) proteins. 
(600X magnification)
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[37, 38]. The minimal chromosomal abnormalities we 
observed in our SCOs are consistent with the copy number 
profiles of some non-functional pituitary adenomas.
Scarce genetic information on pituicytoma is 
available for comparison with SCO. Comparative 
genomic hybridization (CGH) performed on one case of 
pituicytoma showed multiple copy number imbalances, 
with losses on 1p, 14q, and 22q and a gain on 5p [39]. 
This pattern appears distinct from our findings for SCO. 
Overall, we did not identify any significant copy number 
profile changes in SCO that have been reported in pituitary 
adenoma or pituicytoma.
In this report, we present four cases of SCO, using 
whole exome sequencing to reveal abnormal MAPK 
pathway signaling, suggesting it may be a common 
mechanism underlying oncogenesis as a shared phenotypic 
endpoint of various driver mutations. Inhibition of MAPK 
pathway signal transducers, or downstream nodes such 
as MEK, is under active clinical investigation in multiple 
other cancers [40–42]. Consequently, targeted inhibition 
of MAPK pathway signaling may offer an opportunity 
for treatment of spindle cell oncocytomas that cannot be 
controlled by surgical resection alone. Mutational profiling 
of many other tumor types has opened up successful 
personalized targeted medical treatments, and our findings 
suggest spindle cell oncocytomas may also be amenable to 
this approach.
MATERIALS AND METHODS
Sample selection
Analysis of data generated from tumor specimens 
and clinical information was conducted under a Dana-
Farber/Brigham and Women’s Cancer Center (DF/BWCC) 
Institutional Review Board (IRB)-approved protocol. 
Histologic diagnosis was confirmed on all samples by a 
board-certified neuropathologist (S.H.R.) and representative 
paraffin-embedded tissue with average estimated purity 
>70% was selected. Tumor DNA was extracted from 1 mm 
cores and normal DNA was prepared from patient salivary 
samples using standard techniques (Oragene kit, DNA 
Genotek, Kanata, Ontario, Canada; and Qiagen, Valencia, 
CA). The tumor-normal pairs were confirmed by mass 
spectrometric genotyping with an established 48-SNP panel 
(Sequenom, San Diego, CA) [43].
Whole exome sequencing, mutation analysis, and 
copy number analysis
Whole exome sequencing was performed as 
previously described [44]. DNA was sonicated to 150 
bp fragments, size selected with Agencourt AMPure XP 
beads, and ligated to specific barcoded adapors (Illumina 
TruSeq; Illumina Inc., San Diego, CA) for multiplexed 
analysis. Exome hybrid capture was performed using the 
Agilent SureSelect hybrid capture kit (Whole Exome v4; 
Agilent Technologies, Santa Clara, CA) and sequenced on 
a HiSeq 2500 system (Illumina Inc., San Diego, CA). All 
samples achieved at least 80X depth of coverage across 
exons.
Read pairs were aligned to the hg19 reference 
sequence using the Burrows-Wheeler Aligner [45], and 
sample reads sorted and duplicate-marked using SAMtools 
and Picard. Bias in base quality score assignments due to 
flowcell, lane, dinucleotide context, and machine cycle 
were analyzed and recalibrated, and local realignment 
around insertions or deletions (indels) was achieved using 
the Genome Analysis Toolkit (GATK) [46, 47].
Somatic mutations and short indels were called 
and post-filtered using MuTect [48] and IndelLocator 
[49, 50]. These were annotated to genes and compared to 
events in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) using Oncotator and also manually verified in 
the sequence output through visualization in the Integrated 
Genome Viewer (IGV). To analyze somatic copy number 
alterations from whole exome data, we used an allelic 
copy number pipeline, consisting of the ReCapSeg, Allelic 
Capseg and ABSOLUTE algorithms. ReCapseg detects 
total copy ratios from whole-exome sequencing data and 
performs a tangent normalization against a panel of normal 
exomes. Allelic capseg takes the output of ReCapseg and 
splits total copy ratios into homologue-specific copy 
ratios (HSCRs) from segmental estimates of multipotent 
allelic copy-ratios at heterozygous loci incorporating the 
statistical phasing software (BEAGLE) and population 
haplotype panels (HAPMAP3) [51–53]. Allele-specific 
somatic copy number alterations and tumor ploidy status 
were assessed with the ABSOLUTE algorithm [53].
Prediction of possible functional effect of the 
identified mutations was performed using the SIFT 
(Sorting Intolerant from Tolerant) Human Protein 
algorithm (J. Craig Venter Institute) [54]. The SIFT 
prediction score ranges from 0 to 1, and is the scaled 
probability of an amino acid substitution being tolerated. 
Amino acid substitutions with scores that fall below 0.05 
are predicted to affect protein function. Notably, such 
prediction algorithms may be more useful for loss of 
function of tumor suppressor genes than for predicting 
gain of function for proto-oncogenes.
Immunohistochemistry
Diaminobenzidine (DAB) brightfield staining 
was performed according to standard protocols on 5 μm 
paraffin sections [55]. Antigens were retrieved using heat 
and 10 mM sodium citrate buffer (pH 6.0). The following 
primary antibodies were utilized: S100 (DAKO, 1:1000 
dilution), vimentin (DAKO, 1:400), EMA (DAKO, 1:200), 
galectin-3 (Fitzgerald Industries, 1:100), chromogranin 
(Thermo Scientific, 1:4000), GFAP (DAKO, 1:2,000), 
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TTF-1 (DAKO, 1:300), CD68 (DAKO, 1:1000), p-ERK 
(Cell Signaling, 1:200), p-AKT (Cell Signaling, 1:50), 
p-S6 (Cell Signaling, 1:50), and MIB-1 (Ki-67) (Leica, 
1:200). Counterstaining for nuclei was performed using 
Mayer’s hematoxylin stain, and cover slips were mounted 
using Permount (Fisher Scientific).
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